Author: Ken Dropiewski

SentreHEART Announces 400th Patient Enrollment in the Landmark aMAZE Trial

REDWOOD CITY, Calif.–(BUSINESS WIRE)–SentreHEART, Inc., manufacturer of the LARIAT® Suture Delivery Device (LARIAT) for percutaneous left atrial appendage (LAA) closure announces enrollment of the 400th patient in the prospective, multi-center, randomized controlled Trial known as the aMAZE Trial. The Trial is a superiority design and intends to demonstrate the LARIAT procedure […]

Vascular Dynamics Announces Initial Enrollment in Rigorously Designed Hypertension Trial

MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–Vascular Dynamics, Inc. (VDI), a privately held medical device company focused on innovative, minimally invasive device-based solutions for cardiovascular conditions, today announced enrollment of the first patients in an FDA-approved best-in-class pivotal clinical trial. The CALM-2 study is designed to establish safety and efficacy of the novel […]

NeoChord Announces Successful Completion of First Beating Heart Repair Procedures in China

ST. LOUIS PARK, Minn., Sept. 04, 2018 (GLOBE NEWSWIRE) — NeoChord, Inc., a privately-held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation, today announced that it has successfully treated the first patients in Asia using the NeoChord procedure at Queen […]

InspireMD to Present at the H.C. Wainwright 20th Annual Global Investment Conference in New York City

TEL AVIV, ISRAEL, Sept. 04, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE – InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced it will be presenting at the H.C. Wainwright 20th Annual […]

Firehawk® Clinical Data From The TARGET AC European Clinical Trial Has Been Accepted For Publication In The Prestigious Medical Journal The Lancet

SHANGHAI, Sept. 3, 2018 /PRNewswire/ — MicroPort Scientific Corporation (“MicroPort®”, HK:0853) announced today that the clinical trial results for its Firehawk® Rapamycin Target Eluting Coronary Stent System (“Firehawk®”) which conducted a multi-center, randomized controlled trial called TARGET AC has been published online in The Lancet, a world leading medical journal currently ranked second […]

HeartSciences Named Among ‘50 Smartest Companies of the Year 2018’ by The Silicon Review Magazine

SOUTHLAKE, Texas–(BUSINESS WIRE)–Silicon Review, a leading Business and Technology magazine has named HeartSciences, as one of the 50 Smartest Companies of the Year 2018. “The Silicon Review 50 Smartest Companies of the Year 2018 program identifies companies that mastered the discipline of smartness and stood high among the crowd,” said Sreshtha Banerjee, Editor-in-Chief […]

Miracor Medical closes final tranche of Series-D, bringing the round to €30M

AWANS, Belgium, Sept. 4, 2018 /PRNewswire/ — Miracor Medical SA (Miracor Medical) today announced the final closing of the Series D financing round of €30M. The Series D capital will be used to further develop and commercialize the PiCSO® Impulse System. The Series-D round was led by Ming Capital (Shenzhen, China) and co-led by a […]

Acasti Pharma Announces the Election of Its Directors, Changes to Its Stock Option Plan and Other Related Matters Approved at Its AGM

MONTRÉAL, Aug. 29, 2018 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (NASDAQ:ACST) (TSX-V:ACST), a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre® (omega-3 phospholipid) for the treatment of severe hypertriglyceridemia, announced that the following individuals were elected as directors of Acasti Pharma Inc. (“Acasti” […]

Caladrius Biosciences to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

BASKING RIDGE, N.J., Aug. 30, 2018 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a development-stage biopharmaceutical company with multiple technology platforms targeting autoimmune and select cardiovascular indications,  announces today that David J. Mazzo, PhD, President and Chief Executive Officer of Caladrius Biosciences, will present a […]